arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lifevantage Corp

LFVN
$6.70 ▲ +0.14 (+2.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Bullish
auto_awesome

Analytical Summary

Lifevantage Corp shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $82.1M
Dividend Yield 2.46%
Revenue Growth 14.2%
Op. Margin 5.3%
ROIC 28.2%
FCF / Share $0.86
Trailing P/E 8.4x
Price / Book 2.4x
FCF Yield 12.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$228.53M
↑ +14.2%
Net Income Profit after all expenses
$9.80M
↑ +233.8%
Operating Margin Operating profit as % of sales
5.3%
↑ +146.6% 44th
FCF / Share Free cash flow per share
$0.86
↑ +7.4%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
44
Returns
92
Financial Health
100
Cash Quality
69

Dividend History

Dividend / share · sourced from SEC filings
$0.17 Latest / share
-69.7% YoY
+76.5% 4-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 64 quarters